Results from the MenA conjugate vaccine (PsA-TT) randomized controlled trials in infants and young children Executive summary
ثبت نشده
چکیده
To overcome the limited immunogenicity of the meningococcal group A (MenA) polysaccharide (Ps) vaccine, the protein conjugation technology was applied to the development of MenAfriVac® (Serum Institute of India Ltd.). The MenA Ps is covalently conjugated to a protein, which acts as an immunologic carrier. MenAfriVac is a purified MenA polysaccharide tetanus toxoid (TT) conjugated vaccine (10 μg of conjugate per dose). In December 2009, Drug Controller General of India (DCGI), the Indian National Regulatory Agency, granted MenAfriVac a Marketing Authorization (MA) and WHO prequalification was obtained on 23 June 2010.
منابع مشابه
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
BACKGROUND Mass vaccination campaigns of the population aged 1-29 years with 1 dose of group A meningococcal (MenA) conjugate vaccine (PsA-TT, MenAfriVac) in African meningitis belt countries has resulted in the near-disappearance of MenA. The vaccine was tested in clinical trials in Africa and in India and found to be safe and highly immunogenic compared with the group A component of the licen...
متن کاملImmunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali
BACKGROUND Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in the EPI of countries in the African meningitis belt, and this study reports on th...
متن کاملNeisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12–23 Months Following Meningococcal Vaccination
BACKGROUND A group A meningococcal conjugate vaccine, PsA-TT, was licensed in 2010 and was previously studied in a phase 2 clinical trial to evaluate its safety and immunogenicity in African children 12-23 months of age. METHODS Subjects received either PsA-TT; meningococcal group A, C, W, Y polysaccharide vaccine (PsACWY); or Haemophilus influenzae type b conjugate vaccine (Hib-TT). Forty we...
متن کاملA Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians
BACKGROUND A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed to control epidemic group A meningitis in Africa. Documentation of the safety specifications of the PsA-TT vaccine was warranted, with sufficient exposure to detect potential rare vaccine-related adverse reactions. METHODS This phase 3, double-blind, randomized, active co...
متن کاملCommunity Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials
BACKGROUND The Meningitis Vaccine Project (MVP) was established to address epidemic meningitis as a public health problem in sub-Saharan Africa and, to that end, worked to develop a group A meningococcal conjugate vaccine, PsA-TT. METHODS Experiences in 4 clinical trial sites are described. Culturally sensitive collaborative strategies were adopted to manage acceptable communication methods, ...
متن کامل